|
1
|
Miller KD, Nogueira L, Mariotto AB,
Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL and Siegel
RL: Cancer treatment and survivorship statistics, 2019. CA Cancer J
Clin. 69:363–385. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Arnold M, Sierra MS, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global patterns and trends in
colorectal cancer incidence and mortality. Gut. 66:683–691. 2017.
View Article : Google Scholar
|
|
3
|
Ferlay J, Colombet M, Soerjomataram I,
Dyba T, Randi G, Bettio M, Gavin A, Visser O and Bray F: Cancer
incidence and mortality patterns in Europe: Estimates for 40
countries and 25 major cancers in 2018. Eur J Cancer. 103:356–387.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Den Oudsten BL, Traa MJ, Thong MS, Martijn
H, De Hingh IH, Bosscha K and van de Poll-Franse LV: Higher
prevalence of sexual dysfunction in colon and rectal cancer
survivors compared with the normative population: A
population-based study. Eur J Cancer. 48:3161–3170. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu L, Herrinton LJ, Hornbrook MC, Wendel
CS, Grant M and Krouse RS: Early and late complications among
long-term colorectal cancer survivors with ostomy or anastomosis.
Dis Colon Rectum. 53:200–212. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schover LR, van der Kaaij M, van Dorst E,
Creutzberg C, Huyghe E and Kiserud CE: Sexual dysfunction and
infertility as late effects of cancer treatment. EJC Suppl.
12:41–53. 2014. View Article : Google Scholar :
|
|
7
|
Mohammad N, Malvi P, Meena AS, Singh SV,
Chaube B, Vannuruswamy G, Kulkarni MJ and Bhat MK: Cholesterol
depletion by methyl-β-cyclodextrin augments tamoxifen induced cell
death by enhancing its uptake in melanoma. Mol Cancer. 13:2042014.
View Article : Google Scholar
|
|
8
|
Mohammad N, Singh SV, Malvi P, Chaube B,
Athavale D, Vanuopadath M, Nair SS, Nair B and Bhat MK: Strategy to
enhance efficacy of doxorubicin in solid tumor cells by
methyl-β-cyclodextrin: Involvement of p53 and Fas receptor ligand
complex. Sci Rep. 5:118532015. View Article : Google Scholar
|
|
9
|
Rashmi R, Jayachandran K, Zhang J, Menon
V, Muhammad N, Zahner M, Ruiz F, Zhang S, Cho K, Wang Y, et al:
Glutaminase inhibitors induce Thiol-mediated oxidative stress and
radiosensitization in treatment-resistant cervical cancers. Mol
Cancer Ther. 19:2465–2475. 2020.PubMed/NCBI
|
|
10
|
Singh S, Chouhan S, Mohammad N and Bhat
MK: Resistin causes G1 arrest in colon cancer cells through
upregulation of SOCS3. FEBS Lett. 591:1371–1382. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kumar B, Chand V, Ram A, Usmani D and
Muhammad N: Oncogenic mutations in tumorigenesis and targeted
therapy in breast cancer. Curr Mol Biol Rep. 6:116–125. 2020.
View Article : Google Scholar
|
|
12
|
Colotta F, Allavena P, Sica A, Garlanda C
and Mantovani A: Cancer-related inflammation, the seventh hallmark
of cancer: Links to genetic instability. Carcinogenesis.
30:1073–1081. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Unver N and McAllister F: IL-6 family
cytokines: Key inflammatory mediators as biomarkers and potential
therapeutic targets. Cytokine Growth Factor Rev. 41:10–17. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cron L, Allen T and Febbraio MA: The role
of gp130 receptor cytokines in the regulation of metabolic
homeostasis. J Exp Biol. 219:259–265. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rose-John S and Heinrich PC: Soluble
receptors for cytokines and growth factors: Generation and
biological function. Biochem J. 300:281–290. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bromberg JF, Wrzeszczynska MH, Devgan G,
Zhao Y, Pestell RG, Albanese C and Darnell JE Jr: Stat3 as an
oncogene. Cell. 98:295–303. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gritsko T, Williams A, Turkson J, Kaneko
S, Bowman T, Huang M, Nam S, Eweis I, Diaz N, Sullivan D, et al:
Persistent activation of stat3 signaling induces survivin gene
expression and confers resistance to apoptosis in human breast
cancer cells. Clin Cancer Res. 12:11–19. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ma XT, Wang S, Ye YJ, Du RY, Cui ZR and
Somsouk M: Constitutive activation of Stat3 signaling pathway in
human colorectal carcinoma. World J Gastroenterol. 10:1569–1573.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Corvinus FM, Orth C, Moriggl R, Tsareva
SA, Wagner S, Pfitzner EB, Baus D, Kaufmann R, Huber LA, Zatloukal
K, et al: Persistent STAT3 activation in colon cancer is associated
with enhanced cell proliferation and tumor growth. Neoplasia.
7:545–555. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kusaba T, Nakayama T, Yamazumi K, Yakata
Y, Yoshizaki A, Nagayasu T and Sekine I: Expression of p-STAT3 in
human colorectal adenocarcinoma and adenoma; correlation with
clinicopathological factors. J Clin Pathol. 58:833–838. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lin L, Liu A, Peng Z, Lin HJ, Li PK, Li C
and Lin J: STAT3 is necessary for proliferation and survival in
colon cancer-initiating cells. Cancer Res. 71:7226–7237. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lin L, Fuchs J, Li C, Olson V, Bekaii-Saab
T and Lin J: STAT3 signaling pathway is necessary for cell survival
and tumorsphere forming capacity in
ALDH+/CD133+ stem cell-like human colon
cancer cells. Biochem Biophys Res Commun. 416:246–251. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shi W, Yan D, Zhao C, Xiao M, Wang Y, Ma
H, Liu T, Qin H, Zhang C, Li C, et al: Inhibition of IL-6/STAT3
signaling in human cancer cells using Evista. Biochem Biophys Res
Commun. 491:159–165. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang W, Zhao C, Jou D, Lü J, Zhang C, Lin
L and Lin J: Ursolic acid inhibits the growth of colon
cancer-initiating cells by targeting STAT3. Anticancer Res.
33:4279–4284. 2013.PubMed/NCBI
|
|
25
|
Zhao C, Wang W, Yu W, Jou D, Wang Y, Ma H,
Xiao H, Qin H, Zhang C, Lü J, et al: A novel small molecule STAT3
inhibitor, LY5, inhibits cell viability, colony formation, and
migration of colon and liver cancer cells. Oncotarget.
7:12917–12926. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ung N, Putoczki TL, Stylli SS, Ng I,
Mariadason JM, Chan TA, Zhu HJ and Luwor RB: Anti-EGFR therapeutic
efficacy correlates directly with inhibition of STAT3 activity.
Cancer Biol Ther. 15:623–632. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Black RA, Rauch CT, Kozlosky CJ, Peschon
JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P,
Srinivasan S, et al: A metalloproteinase disintegrin that releases
tumour-necrosis factor-alpha from cells. Nature. 385:729–733. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Moss ML, Jin SL, Milla ME, Bickett DM,
Burkhart W, Carter HL, Chen WJ, Clay WC, Didsbury JR, Hassler D, et
al: Cloning of a disintegrin metalloproteinase that processes
precursor tumour-necrosis factor-alpha. Nature. 385:733–736. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Khokha R, Murthy A and Weiss A:
Metalloproteinases and their natural inhibitors in inflammation and
immunity. Nat Rev Immunol. 13:649–665. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dombernowsky SL, Samsøe-Petersen J,
Petersen CH, Instrell R, Hedegaard AM, Thomas L, Atkins KM, Auclair
S, Albrechtsen R, Mygind KJ, et al: The sorting protein PACS-2
promotes ErbB signalling by regulating recycling of the
metalloproteinase ADAM17. Nat Commun. 6:75182015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Grieve AG, Xu H, Künzel U, Bambrough P,
Sieber B and Freeman M: Phosphorylation of iRhom2 at the plasma
membrane controls mammalian TACE-dependent inflammatory and growth
factor signalling. eLife. 6:62017. View Article : Google Scholar
|
|
32
|
Pavlenko E, Cabron AS, Arnold P, Dobert
JP, Rose-John S and Zunke F: Functional characterization of colon
cancer-associated mutations in ADAM17: Modifications in the
pro-domain interfere with trafficking and maturation. Int J Mol
Sci. 20:202019. View Article : Google Scholar
|
|
33
|
Schumacher N and Rose-John S: ADAM17
activity and IL-6 trans-signaling in inflammation and cancer.
Cancers (Basel). 11:112019. View Article : Google Scholar
|
|
34
|
Mustafi R, Dougherty U, Mustafi D,
Ayaloglu-Butun F, Fletcher M, Adhikari S, Sadiq F, Meckel K, Haider
HI, Khalil A, et al: ADAM17 is a tumor promoter and therapeutic
target in western diet-associated colon cancer. Clin Cancer Res.
23:549–561. 2017. View Article : Google Scholar :
|
|
35
|
Muhammad N, Steele R, Isbell TS, Philips N
and Ray RB: Bitter melon extract inhibits breast cancer growth in
preclinical model by inducing autophagic cell death. Oncotarget.
8:66226–66236. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bhattacharya S, Muhammad N, Steele R,
Kornbluth J and Ray RB: Bitter melon enhances natural
killer-mediated toxicity against head and neck cancer cells. Cancer
Prev Res (Phila). 10:337–344. 2017. View Article : Google Scholar
|
|
37
|
Bhattacharya S, Muhammad N, Steele R, Peng
G and Ray RB: Immunomodulatory role of bitter melon extract in
inhibition of head and neck squamous cell carcinoma growth.
Oncotarget. 7:33202–33209. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu T, Ma H, Shi W, Duan J, Wang Y, Zhang
C, Li C, Lin J, Li S, Lv J, et al: Inhibition of STAT3 signaling
pathway by ursolic acid suppresses growth of hepatocellular
carcinoma. Int J Oncol. 51:555–562. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang X, Cui JH, Meng QQ, Li SS, Zhou W
and Xiao S: Advance in anti-tumor mechanisms of shikonin, alkannin
and their derivatives. Mini Rev Med Chem. 18:164–172. 2018.
View Article : Google Scholar
|
|
40
|
Chen X, Yang L, Oppenheim JJ and Howard
MZ: Cellular pharmacology studies of shikonin derivatives.
Phytother Res. 16:199–209. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Guo C, He J, Song X, Tan L, Wang M, Jiang
P, Li Y, Cao Z and Peng C: Pharmacological properties and
derivatives of shikonin-A review in recent years. Pharmacol Res.
149:1044632019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Boulos JC, Rahama M, Hegazy MF and Efferth
T: Shikonin derivatives for cancer prevention and therapy. Cancer
Lett. 459:248–267. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tang JC, Ren YG, Zhao J, Long F, Chen JY
and Jiang Z: Shikonin enhances sensitization of gefitinib against
wild-type EGFR non-small cell lung cancer via inhibition
PKM2/stat3/cyclinD1 signal pathway. Life Sci. 204:71–77. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Thakur R, Trivedi R, Rastogi N, Singh M
and Mishra DP: Inhibition of STAT3, FAK and Src mediated signaling
reduces cancer stem cell load, tumorigenic potential and metastasis
in breast cancer. Sci Rep. 5:101942015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cao HH, Liu DY, Lai YC, Chen YY, Yu LZ,
Shao M and Liu JS: Inhibition of the STAT3 signaling pathway
contributes to the anti-melanoma activities of shikonin. Front
Pharmacol. 11:7482020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tian R, Li Y and Gao M: Shikonin causes
cell-cycle arrest and induces apoptosis by regulating the
EGFR-NF-κB signalling pathway in human epidermoid carcinoma A431
cells. Biosci Rep. 35:352015. View Article : Google Scholar
|
|
47
|
Zou S, Tong Q, Liu B, Huang W, Tian Y and
Fu X: Targeting STAT3 in cancer immunotherapy. Mol Cancer.
19:1452020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chalikonda G, Lee H, Sheik A and Huh YS:
Targeting key transcriptional factor STAT3 in colorectal cancer.
Mol Cell Biochem. 476:3219–3228. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Scheller J, Chalaris A, Garbers C and
Rose-John S: ADAM17: A molecular switch to control inflammation and
tissue regeneration. Trends Immunol. 32:380–387. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Shi W, Ma H, Liu T, Yan D, Luo P, Zhai M,
Tao J, Huo S, Guo J, Li C, et al: Inhibition of
Interleukin-6/glycoprotein 130 signalling by Bazedoxifene
ameliorates cardiac remodelling in pressure overload mice. J Cell
Mol Med. 24:4748–4761. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang Y, van Boxel-Dezaire AH, Cheon H,
Yang J and Stark GR: STAT3 activation in response to IL-6 is
prolonged by the binding of IL-6 receptor to EGF receptor. Proc
Natl Acad Sci USA. 110:16975–16980. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Hunter CA and Jones SA: IL-6 as a keystone
cytokine in health and disease. Nat Immunol. 16:448–457. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Rose-John S: IL-6 trans-signaling via the
soluble IL-6 receptor: Importance for the pro-inflammatory
activities of IL-6. Int J Biol Sci. 8:1237–1247. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Peters M, Blinn G, Solem F, Fischer M,
Meyer zum Büschenfelde KH and Rose-John S: In vivo and in vitro
activities of the gp130-stimulating designer cytokine Hyper-IL-6. J
Immunol. 161:3575–3581. 1998.PubMed/NCBI
|
|
55
|
Elinav E, Nowarski R, Thaiss CA, Hu B, Jin
C and Flavell RA: Inflammation-induced cancer: Crosstalk between
tumours, immune cells and microorganisms. Nat Rev Cancer.
13:759–771. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Chalaris A, Garbers C, Rabe B, Rose-John S
and Scheller J: The soluble Interleukin 6 receptor: Generation and
role in inflammation and cancer. Eur J Cell Biol. 90:484–494. 2011.
View Article : Google Scholar
|
|
57
|
Ying J, Tsujii M, Kondo J, Hayashi Y, Kato
M, Akasaka T, Inoue T, Shiraishi E, Inoue T, Hiyama S, et al: The
effectiveness of an anti-human IL-6 receptor monoclonal antibody
combined with chemotherapy to target colon cancer stem-like cells.
Int J Oncol. 46:1551–1559. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Cross-Knorr S, Lu S, Perez K, Guevara S,
Brilliant K, Pisano C, Quesenberry PJ, Resnick MB and Chatterjee D:
RKIP phosphorylation and STAT3 activation is inhibited by
oxaliplatin and camptothecin and are associated with poor prognosis
in stage II colon cancer patients. BMC Cancer. 13:4632013.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Chang YC, Su CY, Chen MH, Chen WS, Chen CL
and Hsiao M: Secretory RAB GTPase 3C modulates IL6-STAT3 pathway to
promote colon cancer metastasis and is associated with poor
prognosis. Mol Cancer. 16:1352017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Matsusaka S, Hanna DL, Cao S, Zhang W,
Yang D, Ning Y, Sunakawa Y, Okazaki S, Berger MD, Miyamato Y, et
al: Prognostic impact of IL6 genetic variants in patients with
metastatic colorectal cancer treated with bevacizumab-based
chemotherapy. Clin Cancer Res. 22:3218–3226. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Walkiewicz K, Kozieł P, Bednarczyk M,
Błażelonis A, Mazurek U and Muc-Wierzgoń M: Expression of
migration-related genes in human colorectal cancer and activity of
a disintegrin and metalloproteinase 17. BioMed Res Int.
2016:82089042016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Li H, Xiao H, Lin L, Jou D, Kumari V, Lin
J and Li C: Drug design targeting protein-protein interactions
(PPIs) using multiple ligand simultaneous docking (MLSD) and drug
repositioning: Discovery of raloxifene and bazedoxifene as novel
inhibitors of IL-6/GP130 interface. J Med Chem. 57:632–641. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Qiu HY, Zhu X, Luo YL, Lin HY, Tang CY, Qi
JL, Pang YJ, Yang RW, Lu GH, Wang XM, et al: Identification of new
shikonin derivatives as antitumor agents targeting STAT3 SH2
domain. Sci Rep. 7:28632017. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Lin L, Hutzen B, Ball S, Foust E, Sobo M,
Deangelis S, Pandit B, Friedman L, Li C, Li PK, et al: New curcumin
analogues exhibit enhanced growth-suppressive activity and inhibit
AKT and signal transducer and activator of transcription 3
phosphorylation in breast and prostate cancer cells. Cancer Sci.
100:1719–1727. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Xiao H, Bid HK, Jou D, Wu X, Yu W, Li C,
Houghton PJ and Lin J: A novel small molecular STAT3 inhibitor,
LY5, inhibits cell viability, cell migration, and angiogenesis in
medulloblastoma cells. J Biol Chem. 290:3418–3429. 2015. View Article : Google Scholar :
|
|
66
|
Li DD, Zhao CH, Ding HW, Wu Q, Ren TS,
Wang J, Chen CQ and Zhao QC: A novel inhibitor of ADAM17 sensitizes
colorectal cancer cells to 5-fluorouracil by reversing Notch and
epithelial-mesenchymal transition in vitro and in vivo. Cell
Prolif. 51:e124802018. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Sonenberg N and Hinnebusch AG: Regulation
of translation initiation in eukaryotes: Mechanisms and biological
targets. Cell. 136:731–745. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Ryoo HD and Vasudevan D: Two distinct
nodes of translational inhibition in the Integrated Stress
Response. BMB Rep. 50:539–545. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Liang W, Cui J, Zhang K, Xi H, Cai A, Li
J, Gao Y, Hu C, Liu Y, Lu Y, et al: Shikonin induces ROS-based
mitochondria-mediated apoptosis in colon cancer. Oncotarget.
8:109094–109106. 2017. View Article : Google Scholar
|
|
70
|
Han X, Kang KA, Piao MJ, Zhen AX, Hyun YJ,
Kim HM, Ryu YS and Hyun JW: Shikonin exerts cytotoxic effects in
human colon cancers by inducing apoptotic cell death via the
endoplasmic reticulum and mitochondria-mediated pathways. Biomol
Ther (Seoul). 27:41–47. 2019. View Article : Google Scholar
|
|
71
|
Chen Y, Ni J, Gao Y, Zhang J, Liu X, Chen
Y, Chen Z and Wu Y: Integrated proteomics and metabolomics reveals
the comprehensive characterization of antitumor mechanism
underlying Shikonin on colon cancer patient-derived xenograft
model. Sci Rep. 10:140922020. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Chen Y, Si L, Zhang J, Yu H, Liu X, Chen Y
and Wu Y: Uncovering the antitumor effects and mechanisms of
Shikonin against colon cancer on comprehensive analysis.
Phytomedicine. 82:1534602021. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Li MY, Mi C, Wang KS, Wang Z, Zuo HX, Piao
LX, Xu GH, Li X, Ma J and Jin X: Shikonin suppresses proliferation
and induces cell cycle arrest through the inhibition of
hypoxia-inducible factor-1α signaling. Chem Biol Interact.
274:58–67. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
He G, He G, Zhou R, Pi Z, Zhu T, Jiang L
and Xie Y: Enhancement of cisplatin-induced colon cancer cells
apoptosis by shikonin, a natural inducer of ROS in vitro and in
vivo. Biochem Biophys Res Commun. 469:1075–1082. 2016. View Article : Google Scholar : PubMed/NCBI
|
